Zacks: Brokerages Set $50.96 Price Target for Novozymes A/S – (NASDAQ:NVZMY)

Shares of Novozymes A/S – (NASDAQ:NVZMY) have received a consensus broker rating score of 3.00 (Hold) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating.

Brokerages have set a 12 month consensus target price of $50.96 for the company, according to Zacks. Zacks has also given Novozymes A/S – an industry rank of 56 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research downgraded shares of Novozymes A/S – from a “buy” rating to a “hold” rating in a report on Wednesday, June 22nd.

Novozymes A/S – (NASDAQ:NVZMY) opened at 44.305 on Tuesday. The firm’s 50 day moving average price is $44.02 and its 200-day moving average price is $46.04. The stock has a market cap of $13.31 billion and a P/E ratio of 30.832. Novozymes A/S – has a 12-month low of $37.98 and a 12-month high of $49.55.

Novozymes A/S – Company Profile

Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. In June 2013, the Company restructured its sales areas within those segments. The Household Care (old Household Care Enzymes) area comprises cleaning solutions, laundry, dishwashing and microorganism sales for cleaning solutions.

5 Day Chart for NASDAQ:NVZMY

Get a free copy of the Zacks research report on Novozymes A/S – (NVZMY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Novozymes A/S - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novozymes A/S - and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.